

Complete coding begins with me.

Help ensure future packaged payment rates accurately reflect the total cost of nuclear cardiac imaging tests.

Capture the code. Report the use of pharmacologic stress agents when coding for **Level III Nuclear Medicine and Related Services (APC 5593)**.

Current as of June 2020



The cost of the pharmacologic stress agent is accounted for in the packaged payment for Level III Nuclear Medicine imaging procedures. This applies only to Medicare Part B fee-for-service beneficiaries, and only when the procedure occurs in the hospital outpatient setting.

Code Today,

To Prepare for Tomorrow

2020 HOPPS Billing and Payment Rate

CODE	DESCRIPTION	APC	APC TITLE	APC PAYMENT
CPT ^a 78452	Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic); redistribution; and/or rest reinjection	5593	Level III Nuclear Medicine and Related Services	\$1272.19 ¹
CPT 93017	Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report		Packaged Payment	
HCPCS CODE	Pharmacologic stress agent, JXXXX		Packaged Payment	
HCPCS A9500	Technetium tc-99m sestamibi, diagnostic, per study dose		Packaged Payment	

2020
Total Medicare Payment
(Including Beneficiary
Coinsurance)^{b,c}

\$1272.19^d

^aCPT codes 78451, 78452, 78453, and 78454 are assigned to APC 5593.

^bFigure does not reflect the impact of sequestration, which reduces the Medicare portion of payment amounts by 2%, but does not reduce the applicable beneficiary cost sharing. In response to COVID-19, Congress has suspended the impact of sequestration on Medicare payments between May 1, 2020, and December 31, 2020.²

^cBecause pharmacologic stress agents are packaged, the payment adjustment applied to separately payable drugs obtained under the 340B program does not affect payment for pharmacologic stress agents. Hospitals may report the modifiers that indicate whether or not a drug is acquired through the 340B program with the pharmacologic stress agent codes, but are not required to use the modifiers.³


CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; HOPPS = Hospital Outpatient Prospective Payment System.

American Medical Association. Current Procedural Terminology (CPT). Professional edition, 2020. All rights reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

THE PAYMENT RATES IN THIS DOCUMENT REFLECT NATIONAL AVERAGE PAYMENT AMOUNTS. THE ACTUAL PAYMENT TO A HOSPITAL WILL VARY WITH THE APPLICATION OF AN ADJUSTMENT TO REFLECT GEOGRAPHIC VARIATION IN LABOR COSTS. OTHER ADJUSTMENTS MAY ALSO APPLY FOR HIGH-COST CASES OR FOR SERVICES PROVIDED BY CERTAIN TYPES OF HOSPITALS SUCH AS CANCER HOSPITALS.

QUESTION: What would be the impact on the 2020 packaged payment if only 50% of pharmacologic stress agents utilized in 2018 were reported?

ANSWER: The reimbursement rate in 2020 would have decreased from \$1272.19 to \$1193.31.



The 2020 packaged payment rate (\$1272.19) is based on 2018 reporting data.^f

Complete coding begins with you. Capture the code.

^eIt is estimated that failure to code for 50% pharmacologic stress agent utilization during MPI (APC 5593) would result in a 6.2% decrease in HOPPS payments. Analysis by the Moran Company, April 2020.

^fThe 2020 packaged payment rate covers all pharmacologic stress agents included in all HOPPS claims submitted in 2018. This scenario evaluates what would have happened if hospitals had reported only 50% of pharmacologic stress agents utilized in 2018.

IMPORTANT INFORMATION: The coding, coverage, and payment information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims conforming to the requirements of the relevant payer for those products and services rendered. Pharmacies (or any other provider submitting a claim) should contact third-party payers for specific information on their coding, coverage, and payment policies. Information and materials provided by Astellas Pharma Support SolutionsSM are to assist providers and pharmacies, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains at all times with the provider and pharmacy, and information provided by Astellas Pharma Support Solutions or Astellas should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Help ensure future patient access to care by complete coding now.

REFERENCES

1. Centers for Medicare & Medicaid Services. Addendum B Final HOPPS Payment by HCPCS Code for CY 2020. www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientppsaddendum-and-addendum-b-updates/january-2020-0. Accessed 01-23-2020.
2. Coronavirus Aid, Relief, and Economic Security Act, HR 748, 116th Cong, 2nd Sess (2020). www.congress.gov/116/bills/hr748/BILLS-116hr748enr.pdf. Accessed 04-28-2020.
3. Centers for Medicare & Medicaid Services. FFS Program: Billing 340B Modifiers Under the Hospital Outpatient Prospective Payment System (HOPPS) (04-02-2018). www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/billing-340b-modifiers-under-hospital-ops.pdf. Accessed 05-08-2018.

Astellas® and the flying star logo are registered trademarks of Astellas Pharma Inc. All other trademarks or registered trademarks are the property of their respective owners.
©2020 Astellas Pharma US, Inc. All rights reserved. 014-0384-PM 7/20

